Stock Taper 
CLLS
$3.24
▼ DOWN 2.41% (-0.08)
KEY STATISTICS
Market Cap$322.34 M
52w High$5.48
52w Low$2.35
Dividend Yield—
Frequency—
P/E-4.84
Volume4.83K
Shares Out.100.42M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Andre Choulika
ABOUT
SECTOR
Healthcare
WENT PUBLIC
March 24, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
229
PRICE TARGET
Target High$9.00
Target Low$9.00
Target Median$9.00
Target Consensus$9.00
UPCOMING EARNINGS
DateNov 13, 2026
DayFriday
Rev. Est.$15.19M
NOV
13
FRI
PRICE
$3.24 ▼ DOWN 2.41% (−$0.08)About Cellectis S.A.
https://www.cellectis.com ↗Cellectis S.A. is a Paris-based biotech company developing gene-edited CAR T-cell immunotherapies for various cancers, with strategic partnerships and multiple clinical-stage product candidates targeting hematologic malignancies and solid tumors.
INDUSTRY
Biotechnology
A PRODUCT CELLECTIS S.A. IS KNOWN FOR
lasme-cel (UCART22)
Lasme-cel is an off-the-shelf CAR T-cell therapy targeting CD22 for relapsed/refractory B-cell ALL, advancing toward Phase 2 trials as a key innovative, non-patient-specific cancer treatment by Cellectis.
Revenue by Products
| Icon | PRODUCT | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
 | ALLO715 | $5M | $28.5M ▲ | — | — |
 | High Oleic Soyabean Oil | $1.7M | $22.9M ▲ | $27M ▲ | — |
 | Therapeutics | — | — | — | $25.73M |
 | High Oleic Soyabean Meal | $5.6M | — | — | — |
Revenue by Geography
| Map | REGION | FY2021 | FY2022 | FY2023 | FY2025 |
|---|---|---|---|---|---|
 | FRANCE | $30.35M | $19.17M ▼ | $755K ▼ | $72.95M ▲ |
 | UNITED STATES | $26.95M | $0 ▼ | $0 | — |
ETFS HOLDING THIS STOCK
ETFS HOLDING
2
LISTED HERE
2
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
13.65%
HOLDERS
58
TOP 12 OF 58 · RANKED BY POSITION SIZE
Long Focus Capital Management, LLC
B Group, Inc.
Ubs Asset Management Americas Inc
Credit Suisse AG/
Blackrock, Inc.
Taube Hodson Stonex Partners Llp
Macquarie Management Holdings, Inc.
Macquarie Group Ltd
Citadel Advisors LLC
Marshall Wace, Llp
Morgan Stanley
Lpl Financial LLC
RATINGS SNAPSHOT
Overall rating: D+
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1
MOST RECENT ANALYST GRADES
GRADE SUMMARY
MARKET OUTPERFORM 1
OVERWEIGHT 1
2 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 DRTS | $14.98 | COMPARE |
 ANRO | $35.83 | COMPARE |
 SLN | $14.65 | COMPARE |
 LRMR | $3.85 | COMPARE |
 DBVT | $13.56 | COMPARE |
 ACIU | $2.85 | COMPARE |
 AMRN | $13.64 | COMPARE |
 KRRO | $12.13 | COMPARE |